

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

NCT07152002

Status	RECRUITING
Phase	Phase 1
Sponsor	Eli Lilly and Company
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (8)

- Age is 21-65 years old at Singapore Sites
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
- Part A: Body Mass Index (BMI) within the range greater than or equal to 21 and less than 30 kilogram per square meter (kg/m²)
- Part B: a BMI greater than or equal to 27 and less than 45 kg/m²
- Part C: a BMI greater than or equal to 21 and less than 35 kg/m²
- ... and 3 more (see full listing online)

Exclusion (3)

- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
- Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have HbA1c greater than or equal to 6.5% (48 millimole per mole (mmol/mol)) at screening
- Are individuals of childbearing potential (IOCBP).

Locations (3 total)

Collaborative Neuroscience Network - CNS, Los Alamitos, California, United States
ICON Early Phase Services, San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology, Singapore, Singapore